Immune Therapeutics, Inc. (IMUN) Enters Binding Le
Post# of 39
Posted On: 04/21/2016 6:48:52 PM
Immune Therapeutics, Inc. (IMUN) Enters Binding Letter of Intent to Acquire Innovative CAR-T Cell Technology
Before the opening bell, Immune Therapeutics, Inc. (OTCQB: IMUN) announced its entry into a binding letter of intent to acquire Chinese Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy, pending immuno-oncology patents, manufacturing technology and clinical data regarding the aforementioned therapies from Super-T Cell Cancer Company (STCC), a newly-formed corporation. The technology outlined in this letter of intent could play a key role in IMUN’s ongoing efforts to achieve commercial approval for its patented immunotherapies, as described by Christopher Pearce, the company’s chief operating officer, in this morning’s news release:
“This CAR-T cell technology licensing further accelerates IMUN’s growth in the Immuno-Oncology field as we evaluate paths to commercialization both in China and other Emerging Markets,” he stated.
CAR-T cell therapy leverages the power of the patient’s own immune cells to detect and attack cancerous tumors. Data from numerous studies has suggested that regulatory T cells act as key mediators to the development of an immunosuppressed microenvironment that would allow tumors to avoid attack from the immune system and grow unimpeded. Likewise, the CAR-T cocktail therapy has demonstrated promise in early clinical trials for the treatment of blood, renal, cervical and hepatic cancers.
“We are very impressed by the quality of the work done by Professor Shan and his team, and are excited by the safe and efficacious profile of this novel CAR-T cocktail therapy for cancerous diseases,” Noreen Griffin, chief executive officer of IMUN, added in this morning’s news release. “This is the beginning of a long-term strategic partnership between IMUN and STCC. Together, we will expeditiously continue our quest in developing more affordable, safer, and more effective cancer immunotherapy programs.”
Upon completion, acquisition of the Super CAR-T cocktail therapy and its related clinical data is expected to strategically position IMUN to capitalize on the huge demand for affordable cancer therapies in China. Industry data suggests that roughly 4.3 million cases of invasive cancers will be diagnosed in 2016, breaking down to nearly 12,000 new cancer diagnoses with each passing day. According to a study by leading market researcher Research and Markets (http://dtn.fm/I24nc), the oncology market in China is expected to climb to $2.2 billion in 2017, up from just $830 million in 2009.
Despite the rapid growth of the Chinese oncology market, competition in the cancer therapeutics space has remained highly fragmented. The top five players in the space, which is currently led by big pharmaceutical firms of the U.S. and Europe such as Roche/Genentech (OTCQX: RHHBY) and AstraZeneca (NYSE: AZN), occupy less than 30 percent of total market share. IMUN’s management team believes that, upon clinical approval of the CAR-T cocktail therapy, the company could capture as much as five percent of China’s total market share within the first year.
Learn more by visiting www.immunetherapeutics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Before the opening bell, Immune Therapeutics, Inc. (OTCQB: IMUN) announced its entry into a binding letter of intent to acquire Chinese Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy, pending immuno-oncology patents, manufacturing technology and clinical data regarding the aforementioned therapies from Super-T Cell Cancer Company (STCC), a newly-formed corporation. The technology outlined in this letter of intent could play a key role in IMUN’s ongoing efforts to achieve commercial approval for its patented immunotherapies, as described by Christopher Pearce, the company’s chief operating officer, in this morning’s news release:
“This CAR-T cell technology licensing further accelerates IMUN’s growth in the Immuno-Oncology field as we evaluate paths to commercialization both in China and other Emerging Markets,” he stated.
CAR-T cell therapy leverages the power of the patient’s own immune cells to detect and attack cancerous tumors. Data from numerous studies has suggested that regulatory T cells act as key mediators to the development of an immunosuppressed microenvironment that would allow tumors to avoid attack from the immune system and grow unimpeded. Likewise, the CAR-T cocktail therapy has demonstrated promise in early clinical trials for the treatment of blood, renal, cervical and hepatic cancers.
“We are very impressed by the quality of the work done by Professor Shan and his team, and are excited by the safe and efficacious profile of this novel CAR-T cocktail therapy for cancerous diseases,” Noreen Griffin, chief executive officer of IMUN, added in this morning’s news release. “This is the beginning of a long-term strategic partnership between IMUN and STCC. Together, we will expeditiously continue our quest in developing more affordable, safer, and more effective cancer immunotherapy programs.”
Upon completion, acquisition of the Super CAR-T cocktail therapy and its related clinical data is expected to strategically position IMUN to capitalize on the huge demand for affordable cancer therapies in China. Industry data suggests that roughly 4.3 million cases of invasive cancers will be diagnosed in 2016, breaking down to nearly 12,000 new cancer diagnoses with each passing day. According to a study by leading market researcher Research and Markets (http://dtn.fm/I24nc), the oncology market in China is expected to climb to $2.2 billion in 2017, up from just $830 million in 2009.
Despite the rapid growth of the Chinese oncology market, competition in the cancer therapeutics space has remained highly fragmented. The top five players in the space, which is currently led by big pharmaceutical firms of the U.S. and Europe such as Roche/Genentech (OTCQX: RHHBY) and AstraZeneca (NYSE: AZN), occupy less than 30 percent of total market share. IMUN’s management team believes that, upon clinical approval of the CAR-T cocktail therapy, the company could capture as much as five percent of China’s total market share within the first year.
Learn more by visiting www.immunetherapeutics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)Biostax Corp. (BTAX) Stock Research Links
Scroll down for more posts ▼